The Bull Case for Biomarkers

$200 is actually a low price range for all of the biomarkers that you get. If they can attract a segment of the population that won't already have been going through like annual physical exams, then that's where the winning part is. So what's the bull case here? Why is this going to be a huge thing that disrupts the market? The issue is not the tech, because we already have these tests. But the problem is how do you bring in new people? That's it.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.